Scientists at Michigan Medicine have made a significant breakthrough in treating nonalcoholic fatty liver disease (NAFLD), a ...

One of these is non-alcoholic steatohepatitis, or NASH, the fatty liver disease that affects millions of people and which is poised to be one of pharma’s next big growth areas. Novartis ramped ...

Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the risk of liver cirrhosis and ...

Nonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH) are the most common causes of chronic liver disease in industrialized countries. NAFLD has ...

Since symptoms don’t appear until the condition worsens, the only way to detect fatty liver early is through blood tests (LFT ...

Watch what you eat. Fatty buildup in your liver can cause nonalcoholic steatohepatitis and lead to cirrhosis. NASH is linked to high cholesterol, coronary artery disease, obesity, and diabetes.

In the medical field, terminology not only guides clinical understanding and patient communication but also impacts research, ...

The number of liver transplants performed due to obesity-related complications has tripled in the past seven years, according ...

Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solution ...

Raichur: Shilpa Medicare Limited, recently announced that its Investigational New Drug (IND), Nor-Ursodeoxycholic Acid ...